Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy
September 08, 2022 16:05 ET
|
Alpha Tau Medical Ltd.
– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
September 08, 2022 12:30 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...
GRYT Health to Host Fourth Annual Global Virtual Cancer Conference (GVCC) in November 2022
September 08, 2022 09:00 ET
|
GRYT Health
ROCHESTER, N.Y., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GRYT ("grit") Health, a patient experience and research company, is hosting the fourth annual Global Virtual Cancer Conference (GVCC) from Nov....
Love Pharma’s Investment in US Biotech Offers Strategic Industry Advantages and Enhanced Shareholder Value
September 08, 2022 08:30 ET
|
Love Pharma Inc.
NEW YORK, NY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, remains extremely active in shaping itself into...
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
September 08, 2022 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network
September 08, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
Florida Cancer Specialists & Research Institute Receives Top Recognition from International Creative Awards Organization
September 07, 2022 09:00 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- A Florida-focused TV commercial that captures the profound nature of a cancer patient’s journey was recognized with top honors among more than...
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...